{"name":"Lyell Immunopharma, Inc.","slug":"lyell-immunopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"rondecabtagene autoleucel","genericName":"rondecabtagene autoleucel","slug":"rondecabtagene-autoleucel","indication":"Metastatic pancreatic cancer (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"rondecabtagene autoleucel","genericName":"rondecabtagene autoleucel","slug":"rondecabtagene-autoleucel","phase":"phase_3","mechanism":"Rondecabtagene autoleucel is a CAR-T cell therapy that genetically modifies a patient's own T cells to express a chimeric antigen receptor targeting a tumor-associated antigen, enabling the engineered cells to recognize and kill cancer cells.","indications":["Metastatic pancreatic cancer (Phase 3)","Ovarian cancer (Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2026-04-07","type":"pipeline","source":"The Manila Times","summary":"Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference - The Manila Times","headline":"Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMmloZWUxRW90bWVnM1RyUFJvSzVFOGl4UUJUTndQS0daRndmR1pWOU9iMGlZaVk0Z05QaW9USjE2Q1RaYzFXTXNlX3hQdjRfTElUWGtrVUc0cjRLOC0zS1RxNjd6UzBZUnVPbXdCdXRyT2tkWi1aeFlTVFpIMFZFZlEwUjM2WHhhazJrSXk1amtRbnBvLTFsb3FuYV9tdDVXdDRaSnFtUUtubVRkLURnTWpwZURlSC1a?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL) - Stock Titan","headline":"Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPUVRpR2xBLTk5X0xRUl9hSzhCZ3RCaS0zV0xYX0ttWnRaZGxtMlJ1NkZzUWdJVERJRG1fd1RNYnRPQWt1ek5hMktFc2Z3U1FncTVmOGlnM2VYZy1DdWZ2UGdjV00xeVVKOXQyQUJEQ0dOYUg2c2dwR0FZdnRDRUI3Rm41bHZrcXhKS0poQWRSYXFpb1FZQkV0bk1BbWRzVUFIR05SeVdKSEJEQjhYNnZBVw?oc=5","date":"2026-03-23","type":"trial","source":"Seeking Alpha","summary":"Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha","headline":"Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNNG0ybFd2dUM3YU12M196VlEzc1BUV1gtWG1SREJ4dnBXd0Q5cUtNMUVjQUYxUTQta2lWTWtZUE9CSU1sVDRzeUFwNkQzTkllU0ZWRWs4TkpPVnZJOW84d1ZCRXNnTWdveHVGeXpNbzVQU3o0ZjF4U0Z3ODVLZUtQemZibUl4S0hhcmJQcTJSR2l3OWZtYUV6ZzZfeElFZ3AyZ2xESFdHUXRSS3BPaU1Rci1oLVY5YUFTOEk1MkJxcW1UQ05fakpiSkJPdHJ3WmQ5ZmVyMHVJejA?oc=5","date":"2026-03-16","type":"deal","source":"MarketBeat","summary":"Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat","headline":"Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOWGxidGtxajJIMDc5alNFd2hDczF6QlpySWZYdnNqaTdyNEN3aWtNUzVPUE9LZ0FFQ09zZFp5ZFd2SEZxdHc5cjJrZ2ozSVM2Mkg0dUhNQng3VlBJZllCOUZYWXFDLXJNSTNoSVlzX05KQm9vOXFCaGZkcERTLWZLMGd6SzVXbnJ1Z2FuX1Q1N0VwVmJfYjFEeEV5Xy1yREhhSFlUXzlld3NKUzcyZl93d1lMUFZLOFhjNWdXNzVTZENncnZVeUJmSTdDTUVnRHphdm56ZHdYRUYzeGRnNjZoQzNRSTM3dw?oc=5","date":"2026-03-12","type":"earnings","source":"GlobeNewswire","summary":"Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - GlobeNewswire","headline":"Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxPSDFIamFKY3hWTW5yckVDRTBJNktnSmRQYlZLcE1lbEEzMU9SZmpyREJORjlST3djSzFUZC04RDhjcENxWEs1VnA5ajdwQk55Y1RHTjd1dlVweXA0VnlOWkdrS3N0bGduUllMOVFfWXJybFF0dVBHOTRqSHYtVkdmT2NPLUJFRmlocy1ESldSbGpUbWxNcFBEdzVib3RTVlpqQzVVLUg2SkJBQ3hsR2hfRDhBUWJVNkdxWDNscjgzQVlBZXdXckNoZVNoUFVnWGlUQnFmWG5iakRkMmU1WEhSbDJXTEJlOUdkcDQxczlYcERtNEZENGxWXzg4YW5Sc1lVanFKX3BQOFNGRmlRVHlrV0plZ1JIQ1RHcnpVRng0SWc5M1FzOHZaTFpNYXpibEpRUTJTTDduQVBTXzh4LTRacGdGcVVWTzBnSy1hb3Rab1M4X1FfSXN2dURJZlg?oc=5","date":"2026-03-09","type":"pipeline","source":"GlobeNewswire","summary":"Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - GlobeNewswire","headline":"Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Sm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQTXFXUWJ3bUFzY0t4ODdUMm9XTFFDRXlmV0hMZ0hheHl5ZTBIbmJVN054SHJQQ1c2OFFraVZyRjdLSkFrNHd5UzExb2gxNGpjY2Q1aXI0SXhpMVRqYzNpa2V6QldWVXpfclJRR05LSFRhc2dCYnVwYlVvOTNhY3FHYXh3Rm56TDhQS3pLVVN6Nm9sN0QwY2J6aVk3Qm94ZDZpTzNrMUFCLUFQT0d2YjcxMGJHTTZmbk0?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"Cancer cell therapy milestone brings Lyell $50M cash boost and new CFO - Stock Titan","headline":"Cancer cell therapy milestone brings Lyell $50M cash boost and new CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPYmktM0FDUTdBYUhjUHk3Z3ZYWm9VeDBGdEhkbnV5Skc0dVpVaTJWZXIzczI3ZkZ2N1dKQ25fdlFoMlFWdjRkekk3MnBQczRHVlNlUDhPcHVfV0RNdUJpU09FMWVYZ2YtZWF0X0tESGNQZlloX0hIYXBoekdUcC03cjQtNVUtSFVUYmh6Q2ZuUmJZczJsOElJZEJqdFYxZnFPOWJOLTFiRFNEZXU4N0x3dWdxaHV3Rkhsd1hjNFdqcGJGdElyalc2cW8teUtfNVJnZlNWaDMtZl9VeTd4cl9yeW80bEVnYzdTZlB6ZTVxcTBfMkpXdTRYSDBDWmwzeVhiN29vZEpESWsxeW55WHFkMHMxQVFwblFPdUZhUWdRRnFuZTJDQnJtMjlFQkxCT09majd6eEQ5OFA5MnZFZXV1WXZVM1lQZnNGOXZiRkxFRVFrMVU?oc=5","date":"2026-02-12","type":"trial","source":"GlobeNewswire","summary":"Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma - GlobeNewswire","headline":"Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPNkU1elhvRnFzOHByWDdUNXdGLW1tNGVkejVJOGd4RjNzd1RLalN1ZFBGa2xwMS04U3Q5cm5ITEVGSS12VlRZYXA5QXAyNWNfdjNMS0JNLWY3ajNqYlpEbDRpRW5rVVhOVjEyR185VEI5WnVBWGhGTlpLVktxc3JiSTdJVm5VVWx6b3hnTWhtSi00dHJpZThTcVpEdXhjWFI4MFBXV1Bn?oc=5","date":"2025-12-24","type":"trial","source":"Seeking Alpha","summary":"Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha","headline":"Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQb1ZVZklLU25DUVRsVHdVZFJ0aUFPNzd5NzlsNGkwc0NNVzVwRVNQYWNHeVc2UzZKdVBuWlFvRmw3bng1ZGp3aEZieDlyWnZYRHBhSWNYOWZyUElLYTFhZURPRlNpbllOdXR2eUU0VEh5VGZNZksxcnd3MjB6dGdsN3Rvemw3eUgwSDdZR3hFdGR1UVpfalRz?oc=5","date":"2025-12-17","type":"pipeline","source":"Yahoo Finance","summary":"Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain - Yahoo Finance","headline":"Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-22","type":"pipeline","source":"simplywall.st","summary":"Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy - simplywall.st","headline":"Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors mu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPaGJSV1hnbFN4cE5OcWNDTWNfMWVCU1picWs0Z2kweFVmTzYzZWJNcXRTeVpBMUNQNXF4d0tDSmxqdU1VV2RQcGxjWFhJZlVfTzQ5NjgwSG91VnhiZWt1MENIVXJIa3AybXJ3ZmJMNFFQV3RFNm9nRmtpczlTbXNnUGVBaUJiQVY1Z0JNQ2ZQclJUTlF0NGdhLWU5UGxmakNxX1RjSnlLQjdTaXUw?oc=5","date":"2025-11-10","type":"trial","source":"Fierce Biotech","summary":"Lyell hands over $70M-plus in cash, equity for 'impressive' phase 1-stage colorectal cancer CAR-T - Fierce Biotech","headline":"Lyell hands over $70M-plus in cash, equity for 'impressive' phase 1-stage colorectal cancer CAR-T","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}